UNASSIGNED: Realizing the promise of precision medicine in @entity5 therapy depends on identifying and tracking cancerous growths to maximize treatment options and improve @entity1 outcomes. This goal of early detection remains unfulfilled by current clinical imaging techniques that fail to detect lesions due to their small size and suborgan localization. With proper probes, optical imaging techniques can overcome this by identifying the molecular phenotype of @entity5 at both macroscopic and microscopic scales. In this study, the first use of nanophotonic short wave infrared technology is proposed to molecularly phenotype small lesions for more sensitive detection. Here, human serum albumin encapsulated rare-earth nanoparticles (ReANCs) with ligands for targeted lesion imaging are designed. @entity9019 , an antagonist to @entity436 (a classic marker of @entity5 @entity3 ) is adsorbed onto ReANCs to form functionalized ReANCs (fReANCs). fReANCs are able to preferentially accumulate in receptor positive lesions when injected intraperitoneally in a subcutaneous @entity5 model. fReANCs can also target subtissue microlesions at a maximum depth of 10.5 mm in a lung metastatic model of @entity0 . @entity66 identified with fReANCs are 2.25 times smaller than those detected with ReANCs. Thus, an integrated nanoprobe detection platform is presented, which allows target-specific identification of subtissue @entity5 .

XXXX Targeted, Short Wave Infrared (SWIR) Emitting Nanoprobes for Enhanced Deep Tissue Imaging and Micrometastatic Cancer Lesion Detection.

@entity1 :: ('9606', 'Species') :: ['patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity66 :: ('MESH:D004194', 'Disease') :: ['Internal lesions'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancerous lesions', 'tumor', 'cancer', 'tumors'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity9019 :: ('MESH:C088327', 'Chemical') :: ['AMD3100'] @entity436 :: ('7852', 'Gene') :: ['CXCR4']
@entity436 :: (7852,Gene) :: ['CXCR-4']
